在ABCG2多态性和他类药物诱导的不良事件之间的关联:元分析
Da Hoon Lee1, Hae Ji Shin2, Beom Yoon2
1College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
Cardiovascular toxicology
|August 23, 2025
概括
这种ABCG2 rs2231142基因变异与他类药物的毒性增加有关,包括肌肉和肝脏问题. 这一发现凸显了对他类药物治疗的个性化医疗的需要.
科学领域:
- 药物基因组学
- 心血管疾病研究
- 药物新陈代谢
背景情况:
- 类药物对预防心血管疾病至关重要,但可能引起不良反应.
- ATP结合盒子子子家族G成员2 (ABCG2) 基因影响药物代谢.
- 需要澄清ABCG2 rs2231142多态性对他类药物的作用.
研究的目的:
- 系统地审查和元分析ABCG2rs2231142多态性与他类药物诱导的毒性之间的关联.
- 为了澄清之前调查的不确定的发现.
主要方法:
- 进行了全面的文献搜索,确定了七项符合条件的研究.
- 严格的数据提取和包括的研究质量评估.
- 进行元分析以确定整体关联和风险比率.
主要成果:
- 在ABCG2 rs2231142多态性和总体上因他类药物引起的毒性增加之间发现了显著的关联.
- 确定了肌肉 (OR=2.6) 和肝脏 (OR=2.7) 毒性的特定风险.
- 这种多态性会影响他类药物的代谢和药理动力学.
结论:
- 这种ABCG2 rs2231142多态性是他类药物诱导毒性的潜在危险因素.
- 这些发现支持了对他类药物治疗的个性化治疗策略的重要性.
- 需要进一步研究ABCG2在药物不良反应中的作用.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Pharmacovigilance
989
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
989
Factors Affecting Protein-Drug Binding: Patient-Related Factors
114
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
114
Factors Affecting Protein-Drug Binding: Drug Interactions
273
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
273
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33


